Literature DB >> 20926006

Effect of antegrade graft cardioplegia combined with passive graft perfusion in on-pump coronary artery bypass grafting.

M T Goncu1, M Sezen, F Toktas, H Ari, M Gunes, O Tiryakioglu, S Yavuz.   

Abstract

Patients undergoing on-pump coronary artery bypass graft (CABG) with proximal graft anastomosis were randomly divided into groups that received antegrade cardioplegic infusion only via the aortic root (group A) or antegrade cardioplegic infusion via the aortic root and additional cardioplegia via vein or free arterial grafts after completion of each distal anastomosis (group B). The group B patients also received bypass graft perfusion with warm arterial blood just after removal of the cross-clamp until the proximal graft anastomosis was completed. The need for defibrillation and inotropic support during separation from cardiopulmonary bypass (CPB), and total CPB time were significantly lower in group B than in group A. Group B also had significantly lower peak cardiac troponin I levels 12 h after operation compared with group A and this was more pronounced in subgroups with severe right coronary artery stenosis and poor left ventricular ejection fraction than in the whole population. It is concluded that antegrade graft cardioplegia and graft perfusion with warm blood during proximal graft anastomosis may improve myocardial protection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926006     DOI: 10.1177/147323001003800415

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  2 in total

1.  Effects of single antegrade hot shot in comparison with no hot shot administration during coronary artery bypass grafting.

Authors:  Pouya Mirmohammadsadeghi; Mohsen Mirmohammadsadeghi
Journal:  ARYA Atheroscler       Date:  2015-05

2.  Protective effect of active perfusion in porcine models of acute myocardial ischemia.

Authors:  Zanxiang Feng; Zhifu Mao; Shengjun Dong; Baohui Liu
Journal:  Mol Med Rep       Date:  2016-08-24       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.